Invasive Fungal Infections in High-Risk Patients: Report from TIMM-8 2017

References

• Ananda-Rajah MR, Grigg A, Downey MT et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica 97, 459–463 (2012).
   PubMed Web of Science ®Google Scholar
• Neofytos D, Lu K, Hatfield-Seung A et al. Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy. Diagn. Microbiol. Infect. Dis. 75, 144–149 (2013).
   PubMed Web of Science ®Google Scholar
• Tang JL, Kung HC, Lei WC et al. High incidences of invasive fungal infections in acute myeloid leukemia patients receiving induction chemotherapy without systemic antifungal prophylaxis: a prospective observational study in Taiwan. PLoS ONE 10, e0128410 (2015).
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A et al. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. Clin. Infect. Dis. 55, 1515–1521 (2012).
   PubMed Web of Science ®Google Scholar
• Nucci M, Garnica M, Gloria AB et al. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. Clin. Microbiol. Infect. 19, 745–751 (2013).
   PubMed Web of Science ®Google Scholar
• Gomes MZ, Mulanovich VE, Jiang Y, Lewis RE, Kontoyiannis DP. Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011. Antimicrob. Agents Chemother. 58, 865–873 (2014).
   PubMed Web of Science ®Google Scholar
• Girmenia C, Raiola AM, Piciocchi A et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol. Blood Marrow Transplant. 20, 872–880 (2014).
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin. Infect. Dis. 50, 1091–1100 (2010).
   PubMed Web of Science ®Google Scholar
• Corzo-León DE, Satlin MJ, Soave R et al. Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens. Mycoses 58, 325–336 (2015).
   PubMed Web of Science ®Google Scholar
• Omer AK, Ziakas PD, Anagnostou T et al. Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience. Biol. Blood Marrow Transplant. 19, 1190–1196 (2013).
   PubMed Web of Science ®Google Scholar
• Morrissey CO, Chen SC, Sorrell TC et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect. Dis. 13, 519–528 (2013).
   PubMed Web of Science ®Google Scholar
• Doan TN, Kirkpatrick CM, Walker P et al. Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit. J. Antimicrob. Chemother. 71, 497–505 (2016).
   PubMed Web of Science ®Google Scholar
• Cornely OA, Leguay T, Maertens J et al. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. J. Antimicrob. Chemother. 72, 2359–2367 (2017).
   PubMed Web of Science ®Google Scholar
• Henden A, Morris K, Truloff N, Nakagaki M, Kennedy GA. Incidence and outcomes of invasive fungal disease in adult patients with acute lymphoblastic leukemia treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone: implications for prophylaxis. Leuk. Lymphoma 54(6), 1329–1331 (2013).
   PubMed Web of Science ®Google Scholar
• Teng JC, Slavin MA, Teh BW et al. Epidemiology of invasive fungal disease in lymphoproliferative disorders. Haematologica 100, e462–e466 (2015).
   PubMed Web of Science ®Google Scholar
• Wauters J, Baar I, Meersseman P et al. Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Med. 38, 1761–1768 (2012).
   PubMed Web of Science ®Google Scholar
• Bassetti M, Bouza E. Invasive mould infections in the ICU setting: complexities and solutions. J. Antimicrob. Chemother. 72(Suppl. 1), i39–i47 (2017).
   PubMedGoogle Scholar
• Pappas PG, Alexander BD, Andes DR et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 50, 1101–1111 (2010).
   PubMed Web of Science ®Google Scholar
• Ceesay MM, Desai SR, Berry L et al. A comprehensive diagnostic approach using galactomannan, targeted β-d-glucan, baseline computerized tomography and biopsy yields a significant burden of invasive fungal disease in at risk haematology patients. Br. J. Haematol. 168, 219–229 (2015).
   PubMed Web of Science ®Google Scholar
• Colombo AL, de Almeida Júnior JN, Slavin MA, Chen SC, Sorrell TC. Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. Lancet Infect. Dis. 17, e344–e356 (2017).
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 95, 644–650 (2010).
   PubMed Web of Science ®Google Scholar
• Yong MK, Ananda-Rajah M, Cameron PU et al. Cytomegalovirus reactivation is associated with increased risk of late-onset invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a multicenter study in the current era of viral load monitoring. Biol. Blood Marrow Transplant. 23, 1961–1967 (2017).
   PubMed Web of Science ®Google Scholar
• Martino R, Subirá M, Rovira M et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br. J. Haematol. 116, 475–482 (2002).
   PubMed Web of Science ®Google Scholar
• Ravikumar S, Win MS, Chai LY. Optimizing outcomes in immunocompromised hosts: understanding the role of immunotherapy in invasive fungal diseases. Front. Microbiol. 6, 1322 (2015).
   PubMed Web of Science ®Google Scholar
• Chamilos G, Lionakis MS, Kontoyiannis DP et al. Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways. Clin. Infect. Dis. 66, 140–148 (2018).
   PubMed Web of Science ®Google Scholar
• Kyi C, Hellmann MD, Wolchok JD, Chapman PB, Postow MA. Opportunistic infections in patients treated with immunotherapy for cancer. J. Immunother. Cancer 2, 19 (2014).
   PubMedGoogle Scholar
• Herbrecht R, Caillot D, Cordonnier C et al. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation. J. Antimicrob. Chemother. 67, 2731–2738 (2012).
   PubMed Web of Science ®Google Scholar
• Pagano L, Busca A, Candoni A et al. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Rev. 31, 17–29 (2017).
   PubMed Web of Science ®Google Scholar
• Pagano L, Dragonetti G, Cattaneo C et al. Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report. Haematologica 102, e407–e410 (2017).
   PubMed Web of Science ®Google Scholar
• Pagano L, Girmenia C, Mele L et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 86, 862–870 (2001).
   PubMed Web of Science ®Google Scholar
• Ethier MC, Science M, Beyene J, Briel M, Lehrnbecher T, Sung L. Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials. Br. J. Cancer 106, 1626–1637 (2012).
   PubMed Web of Science ®Google Scholar
• Maertens J, Donnelly P, Kibbler C et al. ECIL 19–21 (2013): primary antifungal prophylaxis. www.ebmt.org/Contents/Resources/Library/ECIL/Documents/2014%20ECIL5/ECIL5antifungalprophylaxis%20%2020062014%20Final.pdf.
   Google Scholar
• Patterson TF, Thompson GR, Denning DW et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 63, e1–e60 (2016).
   PubMed Web of Science ®Google Scholar
• Wong GC, Abdul Halim NA, Tan BH. Antifungal prophylaxis with posaconazole is effective in preventing invasive fungal infections in acute myeloid leukemia patients during induction and salvage chemotherapy. Clin. Infect. Dis. 61, 1351–1352 (2015).
   PubMed Web of Science ®Google Scholar
• Schrenk KG, Schnetzke U, Stegemann K, von Lilienfeld-Toal M, Hochhaus A, Scholl S. Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia. J. Cancer Res. Clin. Oncol. 141, 1661–1668 (2015).
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M. The role of primary antifungal prophylaxis in patients with haematological malignancies. Clin. Microbiol. Infect. 20(Suppl. 6), 19–26 (2014).
   PubMedGoogle Scholar
• Penack O, Tridello G, Hoek J et al. Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties. Bone Marrow Transplant. 51, 418–423 (2016).
   PubMed Web of Science ®Google Scholar
• Cho SY, Lee DG, Choi SM et al. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations. Mycoses 58, 565–571 (2015).
   PubMed Web of Science ®Google Scholar
• Busca A, Candoni A, Audisio E et al. Long-lasting protective effect of posaconazole prophylaxis in patients with acute myeloid leukemia receiving allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 22, 2214–2219 (2016).
   PubMedGoogle Scholar
• Neofytos D, Chatzis O, Nasioudis D et al. Epidemiology, risk factors and clinical outcomes of invasive aspergillosis in solid organ transplant recipients in the Swiss Transplant Cohort. Presented at: 8th Trends in Medical Mycology (TIMM). Belgrade, Serbia, 6–9 October 2017 ( Abstract S02.4).
   Google Scholar
• Prattes J, Orasch T, Faserl K et al. Triacetylfusarinine C determination in urine samples from hematological malignancy patients: a potential new biomarker for invasive aspergillosis. Presented at: 8th Trends in Medical Mycology (TIMM). Belgrade, Serbia, 6–9 October 2017 ( Abstract S17.4).
   Google Scholar
• Heimann S, Heinz W, Rachow T, Kessel J, Cornely O, Vehreschild J. Clinical experience with novel posaconazole formulations: a retrospective, multi-centre analysis of patients treated in German hospitals. Presented at: 27th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria, 22–25 April 2017 ( Poster P1730). www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=41882.
   Google Scholar
• Boglione-Kerrien C, Picard S, Tron C et al. Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies. J. Cancer Res. Clin. Oncol. 144, 127–134 (2018).
   PubMed Web of Science ®Google Scholar
• Chin A, Pergam SA, Fredricks DN, Hoofnagle AN, Baker KK, Jain R. Evaluation of posaconazole serum concentrations from delayed-release tablets in patients at high risk for fungal infections. Antimicrob. Agents Chemother. 61(10), pii: e00569–e00617 (2017).
   PubMed Web of Science ®Google Scholar
• Jeong W, Haywood P, Shanmuganathan N et al. Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience. J. Antimicrob. Chemother. 71, 3540–3547 (2016).
   PubMed Web of Science ®Google Scholar
• Jung DS, Tverdek FP, Kontoyiannis DP. Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity. Antimicrob. Agents Chemother. 58, 6993–6995 (2014).
   PubMed Web of Science ®Google Scholar
• Miceli MH, Perissinotti AJ, Kauffman CA, Couriel DR. Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis. Mycoses 58, 432–436 (2015).
   PubMed Web of Science ®Google Scholar
• Cornely OA, Robertson MN, Haider S et al. Pharmacokinetics and safety results from the Phase III randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J. Antimicrob. Chemother. 72, 3406–3413 (2017).
   PubMed Web of Science ®Google Scholar
• Pettit NN, Miceli MH, Rivera CG et al. Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation. J. Antimicrob. Chemother. 72, 2355–2358 (2017).
   PubMed Web of Science ®Google Scholar
• Wright DF, Al-Sallami HS, Jackson PM, Reith DM. Falsely elevated vancomycin plasma concentrations sampled from central venous implantable catheters (portacaths). Br. J. Clin. Pharmacol. 70, 769–772 (2010).
   PubMed Web of Science ®Google Scholar
• Lempers VJ, Alffenaar JW, Touw DJ et al. Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations. J. Antimicrob. Chemother. 69, 2988–2994 (2014).
   PubMed Web of Science ®Google Scholar
• Cuervo G, Garcia-Vidal C, Puig-Asensio M et al. Echinocandins compared with fluconazole for candidemia of a urinary tract source: a propensity score analysis. Clin. Infect. Dis. 64, 1374–1379 (2017).
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Ansaldi F et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med. 41, 1601–1610 (2015).
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Posteraro B, Trecarichi EM et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J. Clin. Microbiol. 45, 1843–1850 (2007).
   PubMed Web of Science ®Google Scholar